Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012, Article ID 871401, 11 pages
http://dx.doi.org/10.1155/2012/871401
Review Article

Extrahepatic Manifestations and Autoantibodies in Patients with Hepatitis C Virus Infection

1Department of Gastroenterology and Neurology, Kagawa University School of Medicine, Kagawa, Japan
2Department of Integrated Medicine, Kagawa University School of Medicine, 1750-1, Ikenobe, Miki-Cho, Kita-Gun, Kagawa 761-0793, Japan

Received 27 April 2012; Revised 13 June 2012; Accepted 13 June 2012

Academic Editor: Domenico Sansonno

Copyright © 2012 Takashi Himoto and Tsutomu Masaki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. L. Zignego, C. Giannini, and C. Ferri, “Hepatitis C virus-related lymphoproliferative disorders: an overview,” World Journal of Gastroenterology, vol. 13, no. 17, pp. 2467–2478, 2007. View at Google Scholar · View at Scopus
  2. K. Koike, “Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH,” Hepatology Research, vol. 33, no. 2, pp. 145–150, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Pawlotsky, M. B. Yahia, C. Andre et al., “Immunological disorders in C virus chronic active hepatitis: a prospective case-control study,” Hepatology, vol. 19, no. 4, pp. 841–848, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. S. J. Hadziyannis, “Nonhepatic manifestations and combined diseases in HCV infection,” Digestive Diseases and Sciences, vol. 41, no. 12, pp. 63s–74s, 1996. View at Google Scholar · View at Scopus
  5. V. Agnello and F. G. De Rosa, “Extrahepatic disease manifestations of HCV infection: some current issues,” Journal of Hepatology, vol. 40, no. 2, pp. 341–352, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Cacoub, C. Renou, E. Rosenthal et al., “Extrahepatic manifestations associated with hepatitis C virus infection: a prospective multicenter study of 321 patients,” Medicine, vol. 79, no. 1, pp. 47–56, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Cacoub, T. Poynard, P. Ghillani et al., “Extrahepatic manifestations of chronic hepatitis C,” Arthritis and Rheumatism, vol. 42, no. 10, pp. 2204–2212, 1999. View at Google Scholar
  8. D. V. Stefanova-Petrova, A. H. Tzvetanska, E. J. Naumova et al., “Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients,” World Journal of Gastroenterology, vol. 13, no. 48, pp. 6518–6528, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Galossi, R. Guarisso, L. Bellas, and C. Puoti, “Extrahepatic manifestations of chronic HCV infection,” Journal of Gastrointestinal and Liver Disease, vol. 16, no. 1, pp. 65–73, 2007. View at Google Scholar
  10. A. J. Czaja, H. A. Carpenter, P. J. Santrach, S. B. Moore, H. F. Taswell, and H. A. Homburger, “Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States,” Journal of Hepatology, vol. 18, no. 3, pp. 342–352, 1993. View at Google Scholar · View at Scopus
  11. B. D. Clifford, D. Donahue, L. Smith et al., “High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C,” Hepatology, vol. 21, no. 3, pp. 613–619, 1995. View at Google Scholar · View at Scopus
  12. P. Muratori, L. Muratori, M. Guidi et al., “Clinical impact of non-organ-specific autoantibodies on response to combined antiviral treatment in patients with hepatitis C,” Clinical Infectious Diseases, vol. 40, no. 2, pp. 501–507, 2005. View at Google Scholar
  13. C. Pallazi, D. Buskila, S. D. Angelo, E. D. Amico, and I. Olivieri, “Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases,” Aitoimmunity Reviews, vol. 11, no. 9, pp. 659–663, 2012. View at Google Scholar
  14. T. Himoto and M. Nishioka, “Autoantibodies in hepatitis C virus-related chronic liver disease,” Hepatitis Monthly, vol. 8, no. 4, pp. 295–303, 2008. View at Google Scholar · View at Scopus
  15. G. V. Gregorio, K. Choudhuri, Y. Ma et al., “Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection,” Clinical and Experimental Immunology, vol. 133, no. 3, pp. 404–413, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. D. P. Bogdanos, K. Choudhuri, and D. Vergani, “Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences,” Liver, vol. 21, no. 4, pp. 225–232, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. F. B. Bianchi, P. Muratori, A. Granito, G. Pappas, S. Ferri, and L. Muratori, “Hepatitis C and autoreactivity,” Digestive and Liver Disease, vol. 39, supplement 1, pp. S22–S24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Ferri, L. Muratori, M. Lenzi, A. Granito, F. B. Bianchi, and D. Vergani, “HCV and autoimmunity,” Current Pharmaceutical Design, vol. 14, no. 17, pp. 1678–1685, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. J. Czaja, H. A. Carpenter, P. J. Santrach, and S. B. Moore, “Immunologic features and HLA associations in chronic viral hepatitis,” Gastroenterology, vol. 108, no. 1, pp. 157–164, 1995. View at Google Scholar
  20. F. Cassani, M. Cataleta, P. Valentini et al., “Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile,” Hepatology, vol. 26, no. 3, pp. 561–566, 1997. View at Google Scholar · View at Scopus
  21. J. C. Luo, S. J. Hwang, C. P. Li et al., “Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: negative role of serum viral titre and genotype,” Journal of Gastroenterology and Hepatology, vol. 13, no. 5, pp. 475–479, 1998. View at Google Scholar · View at Scopus
  22. M. Lenzi, S. Bellentani, G. Saccoccio et al., “Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort,” Gut, vol. 45, no. 3, pp. 435–441, 1999. View at Google Scholar · View at Scopus
  23. M. J. Williams, A. Lawson, K. R. Neal, S. D. Ryder, and W. L. Irving, “Autoantibodies in chronic hepatitis C virus infection and their association with disease profile,” Journal of Viral Hepatitis, vol. 16, no. 5, pp. 325–331, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Chrétien, M. Chousterman, I. A. Alsamad et al., “Non-organ-specific autoantibodies in chronic hepatitis C patients: association with histological activity and fibrosis,” Journal of Autoimmunity, vol. 32, no. 3-4, pp. 201–205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. M. Pawlotsky, F. Roudot-Thoraval, P. Simmonds et al., “Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes,” Annals of Internal Medicine, vol. 122, no. 3, pp. 169–173, 1995. View at Google Scholar · View at Scopus
  26. L. Garcia-Buey, C. Garcia-Monzon, S. Rodriguez et al., “Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C,” Gastroenterology, vol. 108, no. 6, pp. 1770–1777, 1995. View at Google Scholar
  27. F. Lunel, L. Musset, P. Cacoub et al., “Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage,” Gastroenterology, vol. 106, no. 5, pp. 1291–1300, 1994. View at Google Scholar · View at Scopus
  28. V. S. Wong, W. Egner, T. Elsey, D. Brown, and G. J. M. Alexander, “Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection,” Clinical and Experimental Immunology, vol. 104, no. 1, pp. 25–31, 1996. View at Google Scholar · View at Scopus
  29. A. Nagasaki, T. Takahashi, T. Sasaki et al., “Cryoglogulinemia in Japanese patients with chronic hepatitis C virus infection: host genetic and virological study,” Journal of Medical Virology, vol. 65, no. 1, pp. 52–57, 2001. View at Google Scholar
  30. D. Siagris, M. Christofidou, A. Tsamandas, A. Lekkou, K. Thomopoulos, and C. Labropoulou-Karatza, “Cryoglobulinemia and progression of fibrosis in chronic HCV infection: cause or effect?” Journal of Infection, vol. 49, no. 3, pp. 236–241, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. J. C. Brouet, J. P. Clauvel, F. Danon, M. Kleim, and M. Seligmann, “Biologic and clinical significance of cryoglobulins. A report of 86 cases,” American Journal of Medicine, vol. 57, no. 5, pp. 775–788, 1974. View at Google Scholar · View at Scopus
  32. D. Sansonno, G. Lauletta, N. Nisi et al., “Non-enveloped HCV core protein as constitutive antigen of cold-precititable immune complexes in type II mixed cryoglobulinaemia,” Clinical and Experimental Immunology-, vol. 133, pp. 275–282, 2003. View at Google Scholar
  33. D. Sansonno and F. Dammacco, “Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations,” Lancet Infectious Diseases, vol. 5, no. 4, pp. 227–236, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. M. J. Mayo, “Extrahepatic manifestations of hepatitis C infection,” American Journal of the Medical Sciences, vol. 325, no. 3, pp. 135–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Sansonno, F. A. Tucci, B. Ghebrehiwet et al., “Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage,” The Journal of Immunology, vol. 183, no. 9, pp. 6013–6020, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. M. P. Dore, G. Fattovich, A. R. Sepulveda, and G. Realdi, “Cryoglobulinemia related to hepatitis C virus infection,” Digestive Diseases and Sciences, vol. 52, no. 4, pp. 897–907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Saadoun, D. A. Landau, L. H. Calabrese, and P. P. Cacoub, “Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation,” Rheumatology, vol. 46, no. 8, pp. 1234–1242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. W. N. Schmidt, J. T. Stapleton, D. R. LaBrecque et al., “Hepatitis C virus (HCV) infection and cryoglobulinemia: analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology,” Hepatology, vol. 31, no. 3, pp. 737–744, 2000. View at Google Scholar · View at Scopus
  39. Z. Kayali, V. E. Buckwold, B. Zimmerman, and W. N. Schmidt, “Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis,” Hepatology, vol. 36, no. 4 I, pp. 978–985, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Ferri and M. T. Mascia, “Cryoglobulinemic vasculitis,” Current Opinion in Rheumatology, vol. 18, no. 1, pp. 54–63, 2006. View at Google Scholar · View at Scopus
  41. F. Iannuzzella, A. Vaglio, and G. Garini, “Management of hepatitis C virus-related mixed cryoglobulinemia,” American Journal of Medicine, vol. 123, no. 5, pp. 400–408, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Sene, P. Ghillani-Dalbin, V. Thibault et al., “Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus,” Journal of Rheumatology, vol. 31, no. 11, pp. 2199–2206, 2004. View at Google Scholar · View at Scopus
  43. P. Pileri, Y. Uematsu, S. Campagnoli et al., “Binding of hepatitis C virus to CD81,” Science, vol. 282, no. 5390, pp. 938–941, 1998. View at Publisher · View at Google Scholar · View at Scopus
  44. D. T. Fearon and M. C. Carroll, “Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex,” Annual Review of Immunology, vol. 18, pp. 393–422, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Schneider, F. Mackay, V. Steiner et al., “BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth,” Journal of Experimental Medicine, vol. 189, no. 11, pp. 1747–1756, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Fabris, L. Quartuccio, S. Sacco et al., “B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection,” Rheumatology, vol. 46, no. 1, pp. 37–43, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Sène, N. Limal, P. Ghillani-Dalbin, D. Saadoun, J. C. Piette, and P. Cacoub, “Hepatitis C virus-associated B-cell proliferation—the role of serum B lymphocyte stimulator (BLyS/BAFF),” Rheumatology, vol. 46, no. 1, pp. 65–69, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. O. Boyer, D. Saadoun, J. Abriol et al., “CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis,” Blood, vol. 103, no. 9, pp. 3428–3430, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. H. Lee, J. D. Ji, J. E. Yeon, K. S. Byun, C. H. Lee, and G. G. Song, “Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection,” Annals of the Rheumatic Diseases, vol. 57, no. 12, pp. 728–731, 1998. View at Google Scholar · View at Scopus
  50. A. Gad, E. Tanaka, A. Matsumoto et al., “Factors predisposing to the occurrence of cryoglobulinemia in two cohorts of Egyptian and Japanese patients with chronic hepatitis C infection: ethnic and genotypic influence,” Journal of Medical Virology, vol. 70, no. 4, pp. 594–599, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Leone, R. Pellicano, A. Maiocco et al., “Mixed cryoglobulinaemia and chronic hepatitis C virus infection: the rheumatic manifestations,” Journal of Medical Virology, vol. 66, no. 2, pp. 200–203, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Ramos-Casals, L. J. Jara, F. Medina et al., “Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases,” Journal of Internal Medicine, vol. 257, no. 6, pp. 549–557, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. F. G. De Rosa, L. P. Pucillo, R. Coviello et al., “Influence of age and autoimmunity on liver disease in HCV-associated type II mixed cryoglobulinemia,” Human Immunology, vol. 63, no. 9, pp. 751–757, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Lidar, N. Lipschitz, N. Agmon-Levin et al., “Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia,” Clinical Reviews in Allergy and Immunology, vol. 42, no. 2, pp. 238–246, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Tanaka, T. Aiyama, J. Imai, Y. Morishita, T. Fukatsu, and S. Kakumu, “Serum cryoglobulin and chronic hepatitis C virus disease among Japanese patients,” American Journal of Gastroenterology, vol. 90, no. 10, pp. 1847–1852, 1995. View at Google Scholar · View at Scopus
  56. F. J. van der Woude, M. R. Daha, and L. A. Van Es, “The current status of neutrophil cytoplasmic antibodies,” Clinical and Experimental Immunology, vol. 78, no. 2, pp. 143–148, 1989. View at Google Scholar · View at Scopus
  57. P. Lamprecht, O. Gutzeit, E. Csernok et al., “Prevalence of ANCA in mixed cryoglobulinemia and chronic hepatitis C virus infection,” Clinical and Experimental Rheumatology, vol. 21, no. 6, supplement 32, pp. S89–S94, 2003. View at Google Scholar · View at Scopus
  58. M. Cojocaru, I. M. Cojocaru, and S. A. Iacob, “Prevalence of anti-neutrophil cytoplasmic antibodies in patients with chronic hepatitis C infection associated mixed cryoglobulinemia,” Romanian Journal of Internal Medicine, vol. 44, no. 4, pp. 427–431, 2006. View at Google Scholar · View at Scopus
  59. A. Kessel, G. Elias, E. Pavlotzky, E. Zuckerman, I. Rosner, and E. Toubi, “Anti-C-reactive protein antibodies in chronic hepatitis C infection: correlation with severity and autoimmunity,” Human Immunology, vol. 68, no. 10, pp. 844–848, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Sjöwall, K. Cardell, E. A. Boström et al., “High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation,” Human Immunology. In press.
  61. D. Saadoun, S. Sadallah, M. Trendelenburg et al., “Anti-C1q antibodies in hepatitis C virus infection,” Clinical and Experimental Immunology, vol. 145, no. 2, pp. 308–312, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Cacoub, P. Ghillani, R. Revelen et al., “Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia,” Journal of Hepatology, vol. 31, no. 4, pp. 598–603, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Alpa, B. Ferrero, R. Cavallo et al., “Anti-neuronal antibodies in patients with HCV-related mixed cryoglobulinemia,” Autoimmunity Reviews, vol. 8, no. 1, pp. 56–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. F. A. Robey, K. D. Jones, and A. D. Steinberg, “C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro,” Journal of Experimental Medicine, vol. 161, no. 6, pp. 1344–1356, 1985. View at Google Scholar · View at Scopus
  65. I. Gunnarsson, J. Rönnelid, Y. H. Huang et al., “Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus,” British Journal of Rheumatology, vol. 36, no. 1, pp. 32–37, 1997. View at Google Scholar · View at Scopus
  66. D. W. Lienesch, K. E. Sherman, A. Metzger, and G. Q. Shen, “Anti-C1q antibodies in patients with chronic hepatitis C infection,” Clinical and Experimental Rheumatology, vol. 24, no. 2, pp. 183–185, 2006. View at Google Scholar · View at Scopus
  67. P. L. Karlsberg, W. M. Lee, D. L. Casey, C. J. Cockerell, and P. D. Cruz, “Cutaneous vasculitis and rheumatoid factor positivity as presenting signs of hepatitis C virus-induced mixed cryoglobulinemia,” Archives of Dermatology, vol. 131, no. 10, pp. 1119–1123, 1995. View at Google Scholar · View at Scopus
  68. F. G. De Rosa and V. Agnello, “Observations on cryoglobulin testing: I. The association of cryoglobulins containing rheumatoid factors with manifestation of cryoglobulinemic vasculitis,” Journal of Rheumatology, vol. 36, no. 9, pp. 1953–1955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Beddhu, S. Bastacky, and J. P. Johnson, “The clinical and morphologic spectrum of renal cryoglobulinemia,” Medicine, vol. 81, no. 5, pp. 398–409, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. G. B. Knight, L. Gao, L. Gragnani et al., “Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies,” Arthritis and Rheumatism, vol. 62, no. 7, pp. 2152–2159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. P. Youinou, P. L. Meroni, M. A. Khamashta, and Y. Shoenfeld, “A need for standardization of the anti-endothelial-cell antibody test,” Immunology Today, vol. 16, no. 8, pp. 363–364, 1995. View at Publisher · View at Google Scholar · View at Scopus
  72. L. H. van den Berg, C. L. A. Lankamp, A. E. J. de Jager et al., “Anti-sulphatide antibodies in peripheral neuropathy,” Journal of Neurology Neurosurgery and Psychiatry, vol. 56, no. 11, pp. 1164–1168, 1993. View at Google Scholar · View at Scopus
  73. A. Amoroso, M. Berrino, L. Canale et al., “Are HLA class II and immunoglobulin constant region genes involved in the pathogenesis of mixed cryoglobulinemia type II after hepatitis C virus infection?” Journal of Hepatology, vol. 29, no. 1, pp. 36–44, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. P. Cacoub, C. Renou, G. Kerr et al., “Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia,” Arthritis and Rheumatism, vol. 44, no. 9, pp. 2118–2124, 2001. View at Google Scholar
  75. C. Jorgensen, M. C. Legouffe, P. Perney et al., “Sicca syndrome associated with hepatitis C virus infection,” Arthritis and Rheumatism, vol. 39, no. 7, pp. 1166–1171, 1996. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Nagao, S. Hanada, S. Shishido et al., “Incidence of Sjögren's syndrome in Japanese patients with hepatitis C virus infection,” Journal of Gastroenterology and Hepatology, vol. 18, no. 3, pp. 258–266, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Verbaan, J. Carlson, S. Eriksson et al., “Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjogren's syndrome and hepatitis C in Swedish patients,” Journal of Internal Medicine, vol. 245, no. 2, pp. 127–132, 1999. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Ohoka, Y. Tanaka, Y. Amako et al., “Sialadenitis in patients with chronic hepatitis C is not directly related to hepatitis C virus,” Hepatology Research, vol. 27, no. 1, pp. 23–29, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. K. Koike, K. Moriya, K. Ishibashi et al., “Sialadenitis histologically resembling Sjögren syndrome in mice transgenic for hepatitis C virus envelope genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 1, pp. 233–236, 1997. View at Google Scholar · View at Scopus
  80. M. Ramos-Casals, M. García-Carrasco, R. Cervera et al., “Th1/Th2 cytokine imbalance in patients with Sjögren syndrome secondary to hepatitis C virus infection,” Seminars in Arthritis and Rheumatism, vol. 32, no. 1, pp. 56–63, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Ramos-Casals, M. García-Carrasco, M. P. B. Zeron, R. Cervera, and J. Font, “Viral etiopathogenesis of Sjögren's syndrome: role of the hepatitis C virus,” Autoimmunity Reviews, vol. 1, no. 4, pp. 238–243, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Ramos-Casals, L. la Civita, S. de Vita et al., “Characterization of B cell lymphoma in patients with Sj?gren’s syndrome and hepatitis C virus infection,” Arthritis and Rheumatism, vol. 57, no. 1, pp. 161–170, 2007. View at Google Scholar
  83. A. Potthoff, T. Witte, K. Rifai et al., “Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjgren syndrome,” Scandinavian Journal of Gastroenterology, vol. 44, no. 8, pp. 994–1003, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Ramos-Casals, M. GarcÍa-Carrasco, R. Cervera et al., “Hepatitis C virus infection mimicking primary Sjögren syndrome: a clinical and immunologic description of 35 cases,” Medicine, vol. 80, no. 1, pp. 1–8, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Brito-Zeron, S. Retamozo, M. Gandia et al., “Monoclonal gammopathy related to Sjögren syndrome: a key marker of disease prognosis and outcomes,” Journal of Autoimmunity. In press.
  86. S. DeVita, L. Quatuccio, S. Salvin et al., “Cryoglobulinaemia related to Sjögren’s syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy,” Rheumatology, vol. 51, no. 4, pp. 627–633, 2012. View at Google Scholar
  87. C. A. Scott, C. Avellini, L. Desinan et al., “Chronic lymphocytic sialoadenitis in HCV-related chronic liver disease: comparison with Sjogren's syndrome,” Histopathology, vol. 30, no. 1, pp. 41–48, 1997. View at Google Scholar · View at Scopus
  88. C. M. Smyth, S. M. McKiernan, R. Hagan et al., “Chronic hepatitis C infection and sicca syndrome: a clear association with HLA DQB1*02,” European Journal of Gastroenterology and Hepatology, vol. 19, no. 6, pp. 493–498, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. R. W. Wilson, T. T. Provost, and W. B. Bias, “Sjogren's syndrome. Influence of multiple HLA-D region alloantigens on clinical and serologic expression,” Arthritis and Rheumatism, vol. 27, no. 11, pp. 1245–1253, 1984. View at Google Scholar · View at Scopus
  90. M. Deutsch, S. Dourakis, E. K. Manesis et al., “Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy,” Hepatology, vol. 26, no. 1, pp. 206–210, 1997. View at Google Scholar · View at Scopus
  91. N. Ganne-Carrie, A. Medini, E. Coderc et al., “Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study,” Journal of Autoimmunity, vol. 14, no. 2, pp. 189–193, 2000. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Antonelli, C. Ferri, A. Pampana et al., “Thyroid disorders in chronic hepatitis C,” American Journal of Medicine, vol. 117, no. 1, pp. 10–13, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. K. M. Kee, C. M. Lee, J. H. Wang et al., “Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis,” Journal of Gastroenterology and Hepatology, vol. 21, no. 1, part 2, pp. 319–326, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. J. C. Mandac, S. Chaudhry, K. E. Sherman, and Y. Tomer, “The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification,” Hepatology, vol. 43, no. 4, pp. 661–672, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. M. F. Prummel and P. Laurberg, “Interferon-α and autoimmune thyroid disease,” Thyroid, vol. 13, no. 6, pp. 547–551, 2003. View at Google Scholar · View at Scopus
  96. M. Nishioka, S. A. Morshed, K. Kono et al., “Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C,” Journal of Hepatology, vol. 26, no. 5, pp. 992–1000, 1997. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Muratori, D. P. Bogdanos, P. Muratori et al., “Susceptibility to thyroid disorders in hepatitis C,” Clinical Gastroenterology and Hepatology, vol. 3, no. 6, pp. 595–603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. S. J. Hadziyannis, “Skin diseases associated with hepatitis C virus infection,” Journal of the European Academy of Dermatology and Venereology, vol. 10, no. 1, pp. 12–21, 1998. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Jubert, J. M. Pawlotsky, F. Puget et al., “Lichen-planus and hepatitis C virus-related chronic active hepatitis,” Archives of Dermatology, vol. 130, no. 1, pp. 73–76, 1994. View at Google Scholar
  100. Y. Nagao, M. Sata, M. Kage, T. Kameyama, and T. Ueno, “Histopathological and immunohistochemical study of oral lichen planus-associated HCV infection,” European Journal of Internal Medicine, vol. 11, no. 5, pp. 277–282, 2000. View at Publisher · View at Google Scholar · View at Scopus
  101. G. R. Hughes, N. N. Harris, and A. E. Gharavi, “The anticardiolipin syndrome,” The Journal of Rheumatology, vol. 13, no. 3, pp. 486–489, 1986. View at Google Scholar · View at Scopus
  102. Y. Nagao, K. Tsubone, R. Kimura et al., “High prevalence of anticardiolipin antibodies in patients with HCV-associated oral lichen planus,” International Journal of Molecular Medicine, vol. 9, no. 3, pp. 293–297, 2002. View at Google Scholar · View at Scopus
  103. T. Himoto, H. Yoneyama, K. Kurokohchi et al., “Clinical relevance of antibodies to cardiolipin antibodies in chronic hepatitis C,” Journal of Clinical Laboratory Analysis. In press.
  104. J. Y. F. Chang, C. P. Chiang, C. K. Hsiao, and A. Sun, “Significantly higher frequencies of presence of serum autoantibodies in Chinese patients with oral lichen planus,” Journal of Oral Pathology and Medicine, vol. 38, no. 1, pp. 48–54, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. G. Lodi, I. Olsen, A. Piattelli, E. D'Amico, L. Artese, and S. R. Porter, “Antibodies to epithelial components in oral lichen planus (OLP) associated with hepatitis C virus (HCV) infection,” Journal of Oral Pathology and Medicine, vol. 26, no. 1, pp. 36–39, 1997. View at Google Scholar · View at Scopus
  106. M. Carrozzo, S. Gandolfo, G. Lodi et al., “Oral lichen planus in patients infected or noninfected with hepatitis C virus: the role of autoimmunity,” Journal of Oral Pathology and Medicine, vol. 28, no. 1, pp. 16–19, 1999. View at Google Scholar · View at Scopus
  107. T. Himoto, S. Nakai, F. Kinekawa et al., “Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody,” Digestive Diseases and Sciences, vol. 54, no. 2, pp. 360–368, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Moroi, C. Peebles, and M. J. Fritzler, “Autoantibody to centromere (kinetochore) in scleroderma sera,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 3, pp. 1627–1631, 1980. View at Google Scholar · View at Scopus
  109. J. Tojo, H. Ohira, T. Suzuki et al., “Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms,” Hepatology Research, vol. 22, no. 3, pp. 187–195, 2002. View at Publisher · View at Google Scholar · View at Scopus
  110. Y. Muro, N. Azuma, H. Onouchi et al., “Autoepitopes on autoantigen centromere protein-A (CENP-A) are restricted to the N-terminal region, which has no homology with histone H3,” Clinical and Experimental Immunology, vol. 120, no. 1, pp. 218–223, 2000. View at Google Scholar · View at Scopus
  111. W. C. Earnshaw and N. Rothfield, “Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma,” Chromosoma, vol. 91, no. 3-4, pp. 313–321, 1985. View at Google Scholar
  112. Y. Tomer, “Hepatitis C and interferon induced thyroiditis,” Journal of Autoimmunity, vol. 34, no. 3, pp. J322–J326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. W. B. Chan, C. C. Chow, and C. S. Cockram, “Interferon alpha treatment and endocrine disease,” Journal of the Royal Society of Medicine, vol. 96, no. 10, pp. 481–485, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. M. J. Rowley, I. R. Mackay, Q. Y. Chen, W. J. Knowles, and P. Z. Zimmet, “Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus,” Diabetes, vol. 41, no. 4, pp. 548–551, 1992. View at Google Scholar · View at Scopus
  115. C. Betterle, P. Fabris, R. Zanchetta et al., “Autoimmunity against pancreatic islets and other tissues before and after interferon-α therapy in patients with hepatitis C virus chronic infection,” Diabetes Care, vol. 23, no. 8, pp. 1177–1181, 2000. View at Google Scholar · View at Scopus
  116. S. Piquer, C. Hernández, J. Enriquez et al., “Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon,” Journal of Laboratory and Clinical Medicine, vol. 137, no. 1, pp. 38–42, 2001. View at Publisher · View at Google Scholar · View at Scopus
  117. P. Fabris, C. Betterle, N. A. Greggio et al., “Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis,” Journal of Hepatology, vol. 28, no. 3, pp. 514–517, 1998. View at Publisher · View at Google Scholar · View at Scopus
  118. B. Wesche, E. Jaeckel, C. Trautwein et al., “Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C,” Gut, vol. 48, no. 3, pp. 378–383, 2001. View at Publisher · View at Google Scholar · View at Scopus
  119. N. K. Gatselis, S. P. Georgiadou, G. K. Koukoulis et al., “Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 11-12, pp. 1563–1573, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. G. Covini, W. C. Carcamo, E. Bredi et al., “Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C,” Antiviral Therapy. In press.
  121. S. Kakizaki, H. Takagi, M. Murakami, H. Takayama, and M. Mori, “HLA antigens in patients with interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C,” Journal of Hepatology, vol. 30, no. 5, pp. 794–800, 1999. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Martocchia, G. Labbadia, V. Paoletti et al., “Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease,” Neuroendocrinology Letters, vol. 22, no. 1, pp. 49–52, 2001. View at Google Scholar · View at Scopus
  123. C. Ferri, A. Antonelli, M. T. Mascia et al., “HCV-related autoimmune and neoplastic disorders: the HCV syndrome,” Digestive and Liver Disease, vol. 39, supplement 1, pp. S13–S21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. F. Invernizzi, M. Galli, G. Serino et al., “Secondary and essential cryoglobulinemias. Frequency, nosological classification, and long-term follow-up,” Acta Haematologica, vol. 70, no. 2, pp. 73–82, 1983. View at Google Scholar · View at Scopus
  125. A. L. Zignego, C. Giannini, and C. Ferri, “Hepatitis C virus-related lymphoproliferative disorders: an overview,” World Journal of Gastroenterology, vol. 13, no. 17, pp. 2467–2478, 2007. View at Google Scholar · View at Scopus
  126. S. J. Korsmeyer, “Bcl-2: a repressor of lymphocyte death,” Immunology Today, vol. 13, no. 8, pp. 285–287, 1992. View at Google Scholar · View at Scopus
  127. A. L. Zignego, F. Giannelli, M. E. Marrocchi et al., “Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases,” Clinical and Experimental Rheumatology, vol. 15, no. 6, pp. 711–712, 1997. View at Google Scholar · View at Scopus
  128. A. L. Zignego, C. Ferri, F. Giannelli et al., “Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas,” Annals of Internal Medicine, vol. 137, no. 7, pp. 571–580, 2002. View at Google Scholar · View at Scopus
  129. M. Ellis, M. Rathaus, A. Amiel, Y. Manor, A. Klein, and M. Lishner, “Monoclonal lymphocyte proliferation and bcl-2 rearrangement in essential mixed cryoglobulinaemia,” European Journal of Clinical Investigation, vol. 25, no. 11, pp. 833–837, 1995. View at Google Scholar · View at Scopus
  130. K. Machida, K. T. N. Cheng, V. M. H. Sung et al., “Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 12, pp. 4262–4267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  131. P. Andreone, A. L. Zignego, C. Cursaro et al., “Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection,” Annals of Internal Medicine, vol. 129, no. 4, pp. 294–298, 1998. View at Google Scholar · View at Scopus
  132. R. Idilman, A. Colantoni, N. De Maria, S. Alkan, S. Nand, and D. H. Van Thiel, “Lymphoproliferative disorders in chronic hepatitis C,” Journal of Viral Hepatitis, vol. 11, no. 4, pp. 302–309, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. R. Bartl, B. Frisch, and A. Fateh-Moghadam, “Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases,” American Journal of Clinical Pathology, vol. 87, no. 3, pp. 342–355, 1987. View at Google Scholar · View at Scopus
  134. J. Raedle, W. K. Roth, G. Oremek, W. F. Caspary, and S. Zeuzem, “α-Fetoprotein and p53 autoantibodies in patients with chronic hepatitis C,” Digestive Diseases and Sciences, vol. 40, no. 12, pp. 2587–2594, 1995. View at Publisher · View at Google Scholar · View at Scopus
  135. M. E. Perry and A. J. Levine, “Tumor-suppressor p53 and the cell cycle,” Current Opinion in Genetics and Development, vol. 3, no. 1, pp. 50–54, 1993. View at Google Scholar · View at Scopus
  136. A. Yagihashi, K. Asanuma, D. Kobayashi et al., “Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma,” Autoimmunity, vol. 38, no. 6, pp. 445–448, 2005. View at Publisher · View at Google Scholar · View at Scopus
  137. G. Ambrosini, C. Adida, and D. C. Altieri, “A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma,” Nature Medicine, vol. 3, no. 8, pp. 917–921, 1997. View at Publisher · View at Google Scholar · View at Scopus
  138. T. Himoto, S. Kuriyama, J. Y. Zhang, E. K. Chan, M. Nishioka, and E. M. Tan, “Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma,” International Journal of Oncology, vol. 26, no. 2, pp. 314–317, 2005. View at Google Scholar · View at Scopus
  139. T. Himoto, S. Kuriyama, J. Y. Zhang et al., “Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma,” International Journal of Oncology, vol. 27, no. 4, pp. 1079–1085, 2005. View at Google Scholar · View at Scopus
  140. H. S. Hong, S. A. Morshed, S. Tanaka, T. Fujiwara, Y. Ikehara, and M. Nishioka, “Anti-Golgi antibody in rheumatoid arthritis patients recognizes a novel antigen of 79 kDa (doublet) by Western blot,” Scandinavian Journal of Immunology, vol. 36, no. 6, pp. 785–792, 1992. View at Publisher · View at Google Scholar · View at Scopus
  141. L. Mozo, A. Simó, A. Suárez, L. Rodrigo, and C. Gutiérrez, “Autoantibodies to Golgi proteins in hepatocellular carcinoma: case report and literature review,” European Journal of Gastroenterology and Hepatology, vol. 14, no. 7, pp. 771–774, 2002. View at Publisher · View at Google Scholar · View at Scopus
  142. E. Briasoulis, K. Kamposioras, V. Tzovaras et al., “CENP-B specific anti-centromere autoantibodies heralding small-cell lung cancer. A case study and review of the literature,” Lung Cancer, vol. 60, no. 2, pp. 302–306, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. M. Ramos-Casals, M. García-Carrasco, F. López-Medrano et al., “Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection clinical description of 35 cases,” Medicine, vol. 82, no. 2, pp. 87–96, 2003. View at Publisher · View at Google Scholar · View at Scopus
  144. J. F. Dufour, P. Pradat, M. Ruivard et al., “Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases,” European Journal of Gastroenterology and Hepatology, vol. 21, no. 3, pp. 245–253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. S. Panzer, E. Seel, M. Brunner et al., “Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia,” European Journal of Haematology, vol. 77, no. 6, pp. 513–517, 2006. View at Publisher · View at Google Scholar · View at Scopus
  146. S. Aref, T. Sleem, N. E. Menshawy et al., “Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection,” Hematology, vol. 14, no. 5, pp. 277–281, 2009. View at Publisher · View at Google Scholar · View at Scopus
  147. N. Ishizaka, Y. Ishizaka, E. Takahashi et al., “Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening,” The Lancet, vol. 359, no. 9301, pp. 133–135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  148. J. T. Wu and L. L. Wu, “Autoantibodies against oxidized LDL: a potential marker for atherosclerosis,” Clinics in Laboratory Medicine, vol. 17, no. 3, pp. 595–604, 1997. View at Google Scholar · View at Scopus
  149. T. Himoto, H. Yoneyama, A. Deguchi et al., “Relationship between the production of autoantibodies to oxidized low-density lipoprptein and hepatic steatosis in patients with chronic hepatitis C,” Experimental and Therapeutic Medicine, vol. 1, no. 4, pp. 663–668, 2010. View at Google Scholar